QGEN Strangle Strategy
QGEN (Qiagen N.V.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NYSE.
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers.
QGEN (Qiagen N.V.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $6.74B, a trailing P/E of 16.83, a beta of 0.64 versus the broader market, a 52-week range of 32.53-57.82, average daily share volume of 2.0M, a public-listing history dating back to 1996, approximately 6K full-time employees. These structural characteristics shape how QGEN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.64 indicates QGEN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. QGEN pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on QGEN?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current QGEN snapshot
As of May 15, 2026, spot at $33.08, ATM IV 41.00%, IV rank 18.58%, expected move 11.75%. The strangle on QGEN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on QGEN specifically: QGEN IV at 41.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a QGEN strangle, with a market-implied 1-standard-deviation move of approximately 11.75% (roughly $3.89 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated QGEN expiries trade a higher absolute premium for lower per-day decay. Position sizing on QGEN should anchor to the underlying notional of $33.08 per share and to the trader's directional view on QGEN stock.
QGEN strangle setup
The QGEN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With QGEN near $33.08, the first option leg uses a $34.73 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed QGEN chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 QGEN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $34.73 | N/A |
| Buy 1 | Put | $31.43 | N/A |
QGEN strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
QGEN strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on QGEN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on QGEN
Strangles on QGEN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the QGEN chain.
QGEN thesis for this strangle
The market-implied 1-standard-deviation range for QGEN extends from approximately $29.19 on the downside to $36.97 on the upside. A QGEN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current QGEN IV rank near 18.58% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on QGEN at 41.00%. As a Healthcare name, QGEN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to QGEN-specific events.
QGEN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. QGEN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move QGEN alongside the broader basket even when QGEN-specific fundamentals are unchanged. Always rebuild the position from current QGEN chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on QGEN?
- A strangle on QGEN is the strangle strategy applied to QGEN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With QGEN stock trading near $33.08, the strikes shown on this page are snapped to the nearest listed QGEN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are QGEN strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the QGEN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 41.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a QGEN strangle?
- The breakeven for the QGEN strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current QGEN market-implied 1-standard-deviation expected move is approximately 11.75%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on QGEN?
- Strangles on QGEN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the QGEN chain.
- How does current QGEN implied volatility affect this strangle?
- QGEN ATM IV is at 41.00% with IV rank near 18.58%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.